These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26227745)

  • 1. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
    Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
    Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
    Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
    Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
    J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.